Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Sep 09, 2025
Episode
315
Soundcloud
Share
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference.
Dr. Tina Cascone discusses results from the NADIM ADJUVANT Phase III trial. Dr. Jacie Jiaqi Law shares survival outcomes of VATS compared to open lobectomy, and Dr. Corinne Faivre-Finn and Dr. Shankar Siva summarize results from the EA5181 trial of concurrent and consolidation durvalumab after chemoradiation for unresectable NSCLC and hypofractionation vs conventional fractionation for LS SCLC.
Guest
Stephen Liu
MD
Chief of Hematology and Oncology
Georgetown University
Tina Cascone
MD
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Jacie Jiaqi Law
MBBCh
Cardiothoracic Surgery Specialist Trainee (Year 2), Associate Surgery Specialty Lead in Thoracic Oncology,
UK SCTS Academic and Research Division Royal Brompton Hospital
Shankar Siva
M.B.B.S., PhD
Associate Professor, Radiation Oncologist,
Peter MacCallum Cancer Centre
